{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:19:39Z","timestamp":1775708379983,"version":"3.50.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gallipoli Medical Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only \u03b2-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin. Durlobactam is a \u03b2-lactamase inhibitor that may overcome intrinsic resistance mechanisms and enable the use of alternative oral \u03b2-lactam antibiotics. The objective of this study was to determine whether sulbactam\/durlobactam increases the susceptibility of M. abscessus to alternative \u03b2-lactam antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Antibiotic susceptibility testing was performed for durlobactam, meropenem, cefuroxime\/amoxicillin alone, and sulbactam\/durlobactam alone and in combination with meropenem and cefuroxime\/amoxicillin according to Clinical Laboratory Standards Institute (CLSI) standards. These results were then compared with imipenem susceptibility with and without relebactam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sulbactam\/durlobactam significantly lowered the MICs of M. abscessus to meropenem, cefuroxime and cefuroxime\/amoxicillin to MICs comparable to those of imipenem and imipenem\/relebactam. The culture medium used had a significant impact on MIC, with Middlebrook 7H9 having significantly lower MICs for all combinations containing durlobactam compared with CLSI standard CAMHB media.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sulbactam\/durlobactam significantly increased susceptibility to oral and intravenous \u03b2-lactam antibiotics in the form of cefuroxime, cefuroxime\/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to \u03b2-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the \u03b2-lactam combinations studied could result in clinical efficacy for M. abscessus disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf441","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:13:56Z","timestamp":1763558036000},"source":"Crossref","is-referenced-by-count":1,"title":["<i>In vitro<\/i>\n                    efficacy of sulbactam\/durlobactam combined with \u03b2-lactam antibiotics in Australian\n                    <i>Mycobacterium abscessus<\/i>\n                    isolates"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6937-7995","authenticated-orcid":false,"given":"Kirby","family":"Patterson-Fahy","sequence":"first","affiliation":[{"name":"The University of Queensland, Greenslopes Clinical School, Gallipoli Medical Research , Greenslopes, QLD ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Carter","sequence":"additional","affiliation":[{"name":"The University of Queensland, Greenslopes Clinical School, Gallipoli Medical Research , Greenslopes, QLD ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, The Prince Charles Hospital , Chermside, Brisbane, QLD ,","place":["Australia"]},{"name":"Child Health Research Centre, The University of Queensland , South Brisbane, QLD ,","place":["Australia"]},{"name":"Department of Respiratory Medicine, Gold Coast University Hospital , Southport, QLD ,","place":["Australia"]},{"name":"School of Medicine and Dentistry, Health Group, Griffith University , Southport, QLD ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieuan E S","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, The Prince Charles Hospital , Chermside, Brisbane, QLD ,","place":["Australia"]},{"name":"Faculty of Medicine, The University of Queensland, Mayne Medical School , Herston, Brisbane ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-1556","authenticated-orcid":false,"given":"Andrew John","family":"Burke","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of Queensland, Mayne Medical School , Herston, Brisbane ,","place":["Australia"]},{"name":"Department of Infectious Disease, The Prince Charles Hospital , Chermside, Brisbane, QLD ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel M","family":"Thomson","sequence":"additional","affiliation":[{"name":"The University of Queensland, Greenslopes Clinical School, Gallipoli Medical Research , Greenslopes, QLD ,","place":["Australia"]},{"name":"Department of Thoracic Medicine, The Prince Charles Hospital , Chermside, Brisbane, QLD ,","place":["Australia"]},{"name":"MetroSouth Clinical TB Service, Princess Alexandra Hospital , Brisbane ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026011413264917800_dkaf441-B1","doi-asserted-by":"publisher","first-page":"139796","DOI":"10.1016\/j.scitotenv.2020.139796","article-title":"Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001\u20132016","volume":"740","author":"Thomson","year":"2020","journal-title":"Sci Total Environ"},{"key":"2026011413264917800_dkaf441-B2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2026011413264917800_dkaf441-B3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"2026011413264917800_dkaf441-B4","doi-asserted-by":"publisher","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"2026011413264917800_dkaf441-B5","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"2026011413264917800_dkaf441-B6","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2026011413264917800_dkaf441-B7","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2026011413264917800_dkaf441-B8","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026011413264917800_dkaf441-B9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/JB.00606-10","article-title":"The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases","volume":"193","author":"Lavollay","year":"2011","journal-title":"J Bacteriol"},{"key":"2026011413264917800_dkaf441-B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2180-14-75","article-title":"Comparative genomics for mycobacterial peptidoglycan remodelling enzymes reveals extensive genetic multiplicity","volume":"14","author":"Machowski","year":"2014","journal-title":"BMC Microbiol"},{"key":"2026011413264917800_dkaf441-B11","doi-asserted-by":"publisher","first-page":"e01956-20","DOI":"10.1128\/AAC.01956-20","article-title":"First penicillin-binding protein occupancy patterns for 15 \u03b2-lactams and \u03b2-lactamase inhibitors in Mycobacterium abscessus","volume":"65","author":"Sayed","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B12","doi-asserted-by":"publisher","first-page":"e00098-20","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the L,D-transpeptidases and D,D-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B13","doi-asserted-by":"publisher","first-page":"e00866-17","DOI":"10.1128\/AAC.00866-17","article-title":"Mycobacterium abscessus L,D-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins","volume":"61","author":"Kumar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B14","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/jac\/dkae288","article-title":"Dual \u03b2-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare","volume":"79","author":"Longo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026011413264917800_dkaf441-B15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cid\/ciab535","article-title":"\u201cOne-two punch\u201d: synergistic \u00df-lactam combinations for Mycobacterium abscessus and target redundancy in the inhibition of peptidoglycan synthesis enzymes","volume":"73","author":"Nguyen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026011413264917800_dkaf441-B16","doi-asserted-by":"publisher","first-page":"e0139923","DOI":"10.1128\/aac.01399-23","article-title":"Comprehensive stability analysis of 13 \u03b2-lactams and \u03b2-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation","volume":"68","author":"Zhou","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cmi.2024.03.019","article-title":"Dual \u03b2-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease","volume":"30","author":"Pozuelo Torres","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026011413264917800_dkaf441-B18","doi-asserted-by":"publisher","first-page":"e5660","DOI":"10.1371\/journal.pone.0005660","article-title":"Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus","volume":"4","author":"Ripoll","year":"2009","journal-title":"PLoS ONE"},{"key":"2026011413264917800_dkaf441-B19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026011413264917800_dkaf441-B20","doi-asserted-by":"publisher","first-page":"e02440-16","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the \u03b2-lactamase BlaMab by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jac\/dkz433","article-title":"Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab \u03b2-lactamase on the in vitro and intracellular efficacy of imipenem","volume":"75","author":"Le Run","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026011413264917800_dkaf441-B22","doi-asserted-by":"publisher","first-page":"106938","DOI":"10.1016\/j.ijantimicag.2023.106938","article-title":"In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates","volume":"62","author":"Burke","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413264917800_dkaf441-B23","doi-asserted-by":"publisher","first-page":"e0060924","DOI":"10.1128\/mbio.00609-24","article-title":"Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus","volume":"15","author":"Dousa","year":"2024","journal-title":"mBio"},{"key":"2026011413264917800_dkaf441-B24","doi-asserted-by":"publisher","first-page":"e0352921","DOI":"10.1128\/mbio.03529-21","article-title":"Inhibiting Mycobacterium abscessus cell wall synthesis: using a novel diazabicyclooctane \u03b2-lactamase inhibitor to augment \u03b2-lactam action","volume":"13","author":"Dousa","year":"2022","journal-title":"mBio"},{"key":"2026011413264917800_dkaf441-B25","doi-asserted-by":"publisher","first-page":"e0104624","DOI":"10.1128\/aac.01046-24","article-title":"Durlobactam to boost the clinical utility of standard of care \u03b2-lactams against Mycobacterium abscessus lung disease","volume":"69","author":"Negatu","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B26","doi-asserted-by":"publisher","first-page":"e0117424","DOI":"10.1128\/aac.01174-24","article-title":"Durlobactam in combination with \u03b2-lactams to combat Mycobacterium abscessus","volume":"69","author":"Shin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B27","author":"CLSI"},{"key":"2026011413264917800_dkaf441-B28","author":"CLSI"},{"key":"2026011413264917800_dkaf441-B29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3390\/antibiotics12121700","article-title":"Approaches to testing novel \u03b2-lactam and \u03b2-lactam combination agents in the clinical laboratory","volume":"12","author":"Russo","year":"2023","journal-title":"Antibiotics"},{"key":"2026011413264917800_dkaf441-B30","doi-asserted-by":"publisher","first-page":"e01089-18","DOI":"10.1128\/AAC.01089-18","article-title":"Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/d41573-023-00096-8","article-title":"FDA approves new antibiotic combination for drug-resistant pneumonia","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026011413264917800_dkaf441-B32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci Rep"},{"key":"2026011413264917800_dkaf441-B33","doi-asserted-by":"publisher","first-page":"ofab215","DOI":"10.1093\/ofid\/ofab215","article-title":"Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease","volume":"8","author":"Park","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026011413264917800_dkaf441-B34","doi-asserted-by":"publisher","first-page":"106669","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413264917800_dkaf441-B35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/infdis\/jiad007","article-title":"A rough colony morphology of Mycobacterium abscessus is associated with cavitary pulmonary disease and poor clinical outcome","volume":"227","author":"Hedin","year":"2023","journal-title":"J Infect Dis"},{"key":"2026011413264917800_dkaf441-B36","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/jac\/dkx284","article-title":"Effect of \u03b2-lactamase production and \u03b2-lactam instability on MIC testing results for Mycobacterium abscessus","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011413264917800_dkaf441-B37","doi-asserted-by":"publisher","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B38","doi-asserted-by":"publisher","first-page":"e0149225","DOI":"10.1128\/spectrum.01492-25","article-title":"Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus","volume":"13","author":"Shrivastava","year":"2025","journal-title":"Microbiol Spectr"},{"key":"2026011413264917800_dkaf441-B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s44259-024-00054-3","article-title":"Cystic fibrosis sputum media induces an overall loss of antibiotic susceptibility in Mycobacterium abscessus","volume":"2","author":"Baker","year":"2024","journal-title":"NPJ Antimicrob Resist"},{"key":"2026011413264917800_dkaf441-B40","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1128\/AAC.00986-07","article-title":"Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria","volume":"52","author":"Greendyke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B41","doi-asserted-by":"publisher","first-page":"151603","DOI":"10.1016\/j.ijmm.2024.151603","article-title":"Impact of Mycobacteroides abscessus colony morphology on biofilm formation and antimicrobial resistance","volume":"314","author":"Oschmann-Kadenbach","year":"2024","journal-title":"Int J Med Microbiol"},{"key":"2026011413264917800_dkaf441-B42","doi-asserted-by":"publisher","first-page":"e0079022","DOI":"10.1128\/aac.00790-22","article-title":"Strongly bactericidal all-oral \u03b2-lactam combinations for the treatment of Mycobacterium abscessus lung disease","volume":"66","author":"Negatu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264917800_dkaf441-B43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026011413264917800_dkaf441-B44","doi-asserted-by":"publisher","author":"Singh","DOI":"10.1101\/2025.08.05.668504"},{"key":"2026011413264917800_dkaf441-B45","doi-asserted-by":"publisher","first-page":"102503","DOI":"10.1016\/j.tube.2024.102503","article-title":"Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: current practices and recommendations","volume":"147","author":"Dartois","year":"2024","journal-title":"Tuberculosis"},{"key":"2026011413264917800_dkaf441-B46","doi-asserted-by":"publisher","first-page":"e00087-24","DOI":"10.1128\/asmcr.00087-24","article-title":"Successful treatment of macrolide-resistant Mycobacterium abscessus infection using multi-drug regimens including dual \u03b2-lactams and phage therapy: case reports in two children","volume":"1","author":"Shimamura","year":"2025","journal-title":"ASM Case Rep"},{"key":"2026011413264917800_dkaf441-B47","doi-asserted-by":"publisher","first-page":"e096188","DOI":"10.1136\/bmjopen-2024-096188","article-title":"Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial","volume":"15","author":"Jong","year":"2025","journal-title":"BMJ Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf441\/65849364\/dkaf441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf441\/65849364\/dkaf441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:26:53Z","timestamp":1768415213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf441\/8377678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf441","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,12]]},"article-number":"dkaf441"}}